Biocon Entered into a Commercialization Agreement with Juno Pharmaceuticals for Liraglutide to Treat Type 2 diabetes and Obesity in Canada
Shots:
- Biocon & Juno Pharmaceuticals collaborated to commercialize a vertically integrated, complex formulation, Liraglutide for the treatment and management of Type 2 diabetes and obesity
- Biocon will be responsible for obtaining regulatory approval for Liraglutide along with manufacturing and supply of the product in the Canadian market
- The Juno’s goal is to provide the patient access to a cost-effective and efficacious treatment & improving healthcare affordability and innovation for all Canadians through this collaboration. Biocon also has a pipeline of promising novel assets in immunotherapy
Ref: Biocon Biologics | Image: Biocon Biologics
Related Post:- Biocon Biologics Receives EMA’s CHMP Positive Opinion of Yesafili (biosimilar, aflibercept)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
